Search Results
Results found for "Glaxo Inc"
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
Premium Membership pricing increases in 2026, and the 67% Terry’s Corner discount is going away. This year brought 20+ podcast episodes, 40% audience growth, and an 811% increase in new listeners. contributors Launch of The Foundry , supporting strategy and CRO alignment In-person community moments, including
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
You may see: Early stopping → potency distortions Different stopping times → incomparable datasets Curve
- Asking Better Questions in Science: A Practical Guide for Emerging Researchers
In this episode, JB pulls the curtain back on the mindset and tactics he’s used for years—including the
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
AI-assisted probe design Multi-receptor visualization in complex tissue The dream is ambitious and increasingly
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
They are signs of strategic incompleteness .
- Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids
Live-cell high-content screening (HCS) offers an increasingly valuable alternative. , 16 synthetic cannabinoid receptor agonists (SCRAs) were evaluated using a CB2 live-cell HCS assay incorporating Because imaging is captured across thousands of intact cells, each measurement incorporates receptor Moderate displacement (50–70%) : AV18A (68.83%), AV11 (60.78%) Low displacement (<50%) : Compounds including Representative HCS images illustrating CELT331 binding (red) and Hoechst-stained nuclei (blue) across increasing
- How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology
When David later shared early data — including a moment where he realized he could image an entire islet Antibodies As JB continued exploring the biology, a major obstacle emerged: validated antibodies for GPCRs, including GLP-1R, were inconsistent and incompatible with high-resolution imaging. David picked up unexpected chemistry insights — including a well-loved lesson involving acetonitrile They’re also performing increasingly complex imaging experiments that capture receptor dynamics in intact
- How System-Level GPCR Thinking Prevents Discovery Failures
FAQ 🔹 What’s included?
- GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures
Orthosteric dose increases drive continuously stronger responses; NAMs and PAMs have structural ceilings A partial agonist appears neutral until expression or coupling is increased. Dr. NAMs, PAMs, and Subtle Mechanistic Traps Modulators are frequently labeled correctly but characterized incompletely These nonlinearities matter: Competitive inhibition decreases as substrate increases. Uncompetitive inhibition strengthens as substrate increases—opposite of intuition.
- How Collaboration Drives GPCR Discoveries
In research, including the GPCR world collaboration isn’t a luxury. It’s survival. To understand how incretin receptors behave in intact tissue, Hodson needed people who saw problems differently Hodson’s group felt the impact directly: imaging incretin receptors in intact islets and brain slices And interactions with GLP-1 pathways were inconsistent.
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
several performance-limiting factors: variable cell behavior, imaging artifacts, batch effects, and incomplete In this blog, you’ll learn: How HCS works and why it is increasingly central to GPCR-based drug discovery However, their limitations become increasingly important as drug discovery moves toward high-information Key limitations of radioligand assays include: • No spatial information — signals are measured in bulk Incorporating internal controls, including known agonists or antagonists, allows normalization and facilitates
- Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism
Here, the Schild plot becomes a diagnostic tool rather than a checkbox test: Slopes >1 often mean incomplete Common revelations include: Mixtures of receptor subtypes producing hybrid response patterns. Incomplete equilibration , where kinetics distort linearity.
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
In research, acting on incomplete or shaky data can destroy your credibility. Startups demand something different: ✅ Clarity of direction even when the picture is incomplete.
- How GPCR Collaboration Built an Innovation Engine
scientists embedded as “connectors” between programs This design had a strategic effect : talent density increased notes that the absence of individual ownership over physical space or specialized equipment removed the incentives Biotech teams, CRO alliances, and academic consortia face the same challenge: how to align incentives
- From Pipettes to Platforms: The Evolution of GPCR Research
These weren’t quaint inconveniences. They shaped how questions were asked.
- Molecular creativity in drug discovery
. • Inclusive Growth : More access for developing nations, new instructors welcome, and global partnerships FAQ 🔹 What’s included?
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
drug matter beyond the familiar and encourages deliberate exploration of chemical novelty, rather than incremental They offer high specificity , favorable safety , and unique mechanisms , including GPCR modulation through
- A Note from Yamina: Building the Next Chapter of Dr. GPCR
partners, and GPCR experts to help teams move faster — from idea to discovery — while reducing risk and increasing The Foundry will also include Yamina’s Consulting Corner — a place for teams to get tailored scientific For the first time, University courses will be included in Premium Membership , giving members full access GPCR is evolving — thoughtfully, inclusively, and sustainably.
- GPCR Collaboration: From Models to Medicine
Over time, that transparency has built enduring partnerships , including one of Carlsson’s earliest with explain why collaborators return, why projects move forward, and why his model of collaboration is increasingly
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
Common questions in the group include: Can we forecast ligand efficacy or selectivity?
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
Allosteric modulators and biased ligands aren’t exotic outliers—they’re increasingly common outcomes
- Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!
This week's highlight includes congrats to: Miles Thompson , Alexander Hauser , Caroline Gorvin , et
- From Failed Experiments to Predictive GPCR Models
Today, his group includes around ten computational chemists and one in-house medicinal chemist. Unlike protein sequences, small molecule data are often fragmented, inconsistent, or unavailable, making For early-career researchers, the takeaway is direct: GPCR drug discovery will increasingly depend on
- Irreversible Drugs, Real Control: Design for Durable Target Engagement
FAQ 🔹 What’s included?
- Innovative Data-Driven Solutions: The pHSense Revolution
These include overexpression, tags, and fluorescent imaging.
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
Join leading scientists to investigate the most recent advancements in GPCR-targeted drug development, incorporating
- Understanding Enzyme Inhibition In GPCR Discovery Programs
Quick FAQ 🔹 What’s included?
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
Your Membership Includes: Frameworks proven in real discovery programs On-demand lessons designed for
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
Fast FAQ 🔹 What’s included?
- The Truth About GPCR Product Launches: Years in the Making
Why This Matters: The GPCR toolkit scientists use today—cAMP, IP-One, and now pHSense—didn’t evolve incrementally





























